Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S394000, C514S412000, C514S411000, C514S466000, C514S443000, C546S334000, C548S309700, C548S439000, C548S492000, C549S058000, C549S437000, C549S443000
Reexamination Certificate
active
10896614
ABSTRACT:
The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
REFERENCES:
patent: 4067904 (1978-01-01), Comer et al.
patent: 4235919 (1980-11-01), Berthold
patent: 4289883 (1981-09-01), Tominaga et al.
patent: 4302588 (1981-11-01), Tominaga et al.
patent: 4332787 (1982-06-01), Homcy et al.
patent: 4376125 (1983-03-01), Brooker et al.
patent: 5763569 (1998-06-01), Brown et al.
patent: 5786356 (1998-07-01), Bell et al.
patent: 6022894 (2000-02-01), Del Mar et al.
patent: 6294531 (2001-09-01), Barmore et al.
patent: 6432656 (2002-08-01), Del Mar et al.
patent: 6521667 (2003-02-01), Del Mar et al.
patent: 6818660 (2004-11-01), Kotecha et al.
patent: 6864267 (2005-03-01), Bhatnagar et al.
patent: 1065894 (1979-11-01), None
patent: 636856 (1983-06-01), None
patent: 2400658 (1974-07-01), None
patent: 2502993 (1975-09-01), None
patent: 2530613 (1976-05-01), None
patent: 2711719 (1977-09-01), None
patent: 2830211 (1979-02-01), None
patent: 2914166 (1980-10-01), None
patent: 2943406 (1981-05-01), None
patent: 2944222 (1981-05-01), None
patent: 3301198 (1984-07-01), None
patent: 3416976 (1984-11-01), None
patent: 4040186 (1991-05-01), None
patent: 4017019 (1991-11-01), None
patent: 298506 (1992-02-01), None
patent: 0002792 (1979-07-01), None
patent: 0009075 (1980-04-01), None
patent: 0095454 (1983-11-01), None
patent: 0188361 (1986-07-01), None
patent: 0355583 (1990-02-01), None
patent: 421076 (1975-09-01), None
patent: 442062 (1975-10-01), None
patent: 480066 (1979-04-01), None
patent: 1058822 (1967-02-01), None
patent: 1129072 (1968-10-01), None
patent: 1199037 (1970-07-01), None
patent: 1 518 689 (1975-09-01), None
patent: 2192394 (1988-01-01), None
patent: 52108980 (1977-09-01), None
patent: 56008319 (1981-01-01), None
patent: 57080321 (1982-05-01), None
patent: 9220642 (1992-11-01), None
patent: 9304373 (1993-03-01), None
patent: 9418959 (1994-09-01), None
patent: 9500493 (1995-01-01), None
patent: 9511221 (1995-04-01), None
Baldwin, Chemical Abstracts, vol. 102, abstract 62238, 1985.
Cohnen et al., Chemical Abstracts, vol. 105:97342, 1986.
Ferris, Chemical Abstracts, vol. 97:144754, 1982.
Fisher et al., Chemical Abstracts, vol. 113:230179, 1990.
Frickel et al., Chemical Abstracts, vol. 95, abstract 62175, 1981.
Frickel et al., Chemical Abstracts, vol. 95, abstract 115563, 1981.
Haynes, Chemical Abstracts, vol. 95:197759, 1981.
Howe et al., Chemical Abstracts, vol. 72:100615, 1970.
Imperial Chemical Industries Ltd, Chemical Abstracts, vol. 66:85645, 1966.
Imperial Chemical Industries Ltd, Chemical Abstracts, vol. 67:99851, 1967.
Knolle et al., Chemical Abstracts, vol. 102:45782, 1985.
Kottmann et al., Chemical Abstracts, vol. 117:40490, 1992.
Kumar et al., Chemical Abstracts, vol. 96:52124, 1982.
Kumar et al., Chemical Abstracts, vol. 101:23414, 1984.
McClure et al., Chemical Abstracts, vol. 99:32759, 1983.
Schlager, Chemical Abstracts, vol. 100:139086, 1984.
Schromm et al., Chemical Abstracts, vol. 99:5636, 1983.
Schromm et al., Chemical Abstracts, vol. 101:19139, 1984.
Summ et al., Chemical Abstracts, vol. 115:183087, 1991.
Weber et al., Chemical Abstracts, vol. 68:59250, 1968.
Abrahamsson et al., “The β1- and β2-Adrenoceptor Affinity of Atenolol and Metoprolol: A Receptor-Binding Study Performed With Different Radioligands in Tissues from the Rat, The Guinea Pig, and Man,”Biochemical Pharmacology37(2):203-208 (1988).
Aggerbeck et al., “Characterization of the α-Adrenoreceptor of Rat Liver Plasma Membrane, Structure Affinity relationship and role of the aralkyl substituent on the amino group,”Recent Advances in the Pharmacology of Adrenoceptors: Proceedings of a Satellite Symposium of the 7th International Congress of Pharmacology held at Owens Park, Manchesterpp. 345-346 (1970).
Aggerbeck et al., “N-arlkyl Substitution Increases the Affinity of Adrenergic Drugs for the α-Adrenoceptor in Rat Liver,”Br. I. Pharmacol.65(1):155-159 (1979).
Auerbach et al., “Neonatal Rat Pinealocytes: Typical and Atypical Characteristics of [125I]Iodohydroxybenzylpindolol Binding and Adenosine 3', 5'-Monophosphate Accumulation,”Endocrinology108(2):559-567 (1981).
Aurbach et al., “β-Adrenergic Receptor: Stereospecific Interaction of Iodinated β-Blocking Agent with High Affinity Site,”Science186:1223-1224 (1974).
Bakardjieva et al., “Modulation of the β-Receptor Adenylate Cyclase Interactions in Cultured Chang Liver Cells by Phospholipid Enrichment,”Biochemistry18(14):3016-3023 (1979).
Baker et al., “The Synthesis of N-Alkylated ρ-Chlorophentermine Derivatives and Their Effects on Release of 5-Hydroxytryptamine From Rat Striatumin Vitro,” Canadian Journal of Pharmaceutical Sciences15(4):71-74 (1980).
Bearer et al., “Iodohydroxybenzylpindolol: Preparation, Purification, Localization of Its Iodine to the Indole Ring, and Characterization as a Partial Agonist,”Molecular Pharmacology17(3):328-338 (1980).
Bilezikian et al., “Structure-Binding Activity Analysis of Beta-Adrenergic Amines - II. Binding to the Beta Receptor and Inhibition of Adenylate Cyclase,”Biochemical Pharmacology27(10):1455-1461(1978).
Braun et al., “The Interaction of Mn2+with Turkey Erythrocyte Adenylate Cyclase,”Biochimica et Biophysica Acta705(1):55-62 (1982).
Brown et al., “β-Adrenergic Receptor Interactions: Characterization of Iodohydroxylbenzylpindolol As A Specific Ligand,”J. Biol. Chem.251(5):1232-1238 (1976).
Brown et al., “β-Adrenergic Receptor Interactions: Direct Comparison of Receptor Interaction and Biological Activity,”J. Biol. Chem.251(5):1239-1246 (1976).
Brown et al., “Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid,”Nature366:575-580 (1993).
Brown et al., “Direct Determination of Ligand Interactions with Beta-Adrenergic Receptors on Intact Turkey Erythrocytes: Correlation of Binding with Biological Activity,”Endocrinology99(5):1370-1376 (1976).
Brown et al., “Neomycin Mimics the Effects of High Extracellular Calcium Concentrations on Parathyroid Function in Dispersed Bovine Parathyroid Cells,”Endocrinology128:3047-3054 (1991).
Burgisser et al., “Anomalous Equilibrium Binding Properties of High-Affinity Racemic Radioligands,”Molecular Pharmacology19(2):205-216 (1981).
Bylund and Snyder, “Beta Adrenergic Receptor Binding in Membrane Preparations from Mammalian Brain,”Molecular Pharmacology12(4):568-580 (1976).
Bylund et al., “Beta Adrenergic Receptor Labeling In Intact Animals with125I-Hydroxybenzylpindolol,”The Journal of Pharmacology and Experimental Therapeutics201(3):644-653 (1977).
Castedo et al., “β-Adrenergic Blockers: Synthesis of R-1-[(1,1-dimethyl-2-phenylethyl) amino]- 3-(3,4-dichlorophenoxy)-2-propanol,”Anales De Quimica,Ser. C, 80(3):291-294 (1984).
Chen and Brown, “The Diltiazem Analog TA-3090 Mimics the Actions of High Extracellular Ca2+on Parathyroid Function in Dispersed Bovine Parathyroid Cells,”Journal of Bone and Mineral Research5:581-587 (1990).
Condon et al., “Nondepressant β-Adrenergic Blocking Agents. 1. Substituted 3-Amino-1-(5,6,7,8-tetrahydro-1-naphthoxy)-2-propanols,”J. Med. Chem.21(9):913-922(1978).
Crowther et al., “β-Adrenergic Blocking Agents. 12. Heterocyclic Compounds Related to Propranolol,”J. Med. Chem.15(3):260-266 (1972).
Dax and Partilla, “Adrenergic Ligand Liposolubility in Membranes: Direct Assessment in a Beta-Adrenergic Binding System,”Molecular Pharmacology22(1):5-7 (1982).
Dax et al., “Quantitation of Beta Adrenergic Receptors in Rat
Barmore Robert M.
Callahan James F.
Del Mar Eric G.
Keenan Richard M.
Kotecha Nikesh R.
Brinks Hofer Gilson & Lione
NPS Pharmaceuticals Inc.
O'Sullivan Peter
LandOfFree
Calcilytic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcilytic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcilytic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797849